

## **Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent**

LEXINGTON, Mass.--(BUSINESS WIRE)-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No. 9,249,149 (the '149 patent). The denial of Incyte's IPR petition upholds the validity of the '149 patent that includes claims covering CTP-543, the Company's investigational compound for the treatment of alopecia areata.

"We are very pleased that the PTAB did not institute the IPR, and that our composition-of-matter patent relating to CTP-543 remains valid and enforceable," stated Roger Tung, President and Chief Executive Officer of Concert Pharmaceuticals. "This is the second case in which the PTAB has elected not to institute an IPR challenge to a deuterated compound based on a pre-existing drug and further supports Concert's technology approach."

In April 2017, Incyte filed a petition challenging the validity of the '149 patent. Documents relating to the IPR can be accessed online at: <http://www.concertpharma.com/technology-overview/intellectual-property/>

### **About Concert**

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company focused on applying its [DCE Platform®](#) (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a [broad pipeline](#) of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit [www.concertpharma.com](http://www.concertpharma.com).

### **Cautionary Note on Forward Looking Statements**

Any statements in this press release about our future expectations, plans and prospects, including statements about the strength of Concert's intellectual property, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171019006221/en/>

Investors  
Concert Pharmaceuticals, Inc.  
Justine Koenigsberg, 781-674-5284  
[ir@concertpharma.com](mailto:ir@concertpharma.com)

or  
Media  
The Yates Network  
Kathryn Morris, 845-635-9828  
[kathryn@theyatesnetwork.com](mailto:kathryn@theyatesnetwork.com)

Source: Concert Pharmaceuticals, Inc.

